Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Neoplasma is Scopus-indexed (Q2, CiteScore 4.8), WoS SCIE. Published by AEPress, s.r.o..
Checked against the index lists dated .
ISSN 0028-2685Verify ISSN ↗1338-4317Verify ISSN ↗
Publisher: AEPress, s.r.o.
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Oncology | 169 / 428 | 60th | Q2 |
| Cancer Research | 135 / 233 | 42nd | Q3 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1957–2025, best quartile Q2, CiteScore 4.8.
Neoplasma is Q2 in Oncology (rank 169 of 428) and Q3 in Cancer Research (rank 135 of 233), by CiteScore 2025.
Neoplasma is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 4.8, which places it in quartile Q2 at the 60th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.586, quartile Q2, with an H-index of 62.
Neoplasma is published by AEPress, s.r.o. Its print ISSN is 0028-2685 and its online ISSN is 1338-4317.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Neoplasma has an h-index of 58 and a 2-year mean of 2.17 citations per paper (OpenAlex). Its Scopus CiteScore is 4.8, quartile Q2. On 2-year citations it ranks #176 of 424 Scopus journals in Oncology.
Neoplasma published 50 papers in 2025; its busiest recent year was 2020 with 166. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 100 research articles (2024–2026), authors are most often from China (73%), Slovakia (18%) and Czechia (3.5%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 2 retracted papers are recorded (1.1 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.